Skip to main content
. 2022 Mar 18;21:44. doi: 10.1186/s12933-022-01478-9

Table 2.

Factors associates with cardiovascular events

Univariate Multivariate
Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Age, years 1.029 (0.993–1.067) 0.119
Male sex 1.346 (0.633–2.862) 0.440
Body mass index, kg/m2 0.996 (0.920–1.078) 0.913
Hypertension 0.975 (0.459–2.071) 0.947
Dyslipidemia 0.931 (0.446–1.944) 0.850
Current Smoker 1.570 (0.722–3.416) 0.441
β-blocker 0.503 (0.152–1.662) 0.255
Calcium channel blocker 1.507 (0.736–3.085) 0.262
ACE-I or ARB 0.956 (0.471–1.939) 0.900
Statin 0.669 (0.321–1.398) 0.285
Insulin therapy 0.807 (0.348–1.876) 0.619
Oral antihyperglycemic drugs 0.849 (0.420–1.719) 0.650
Metformin 0.411 (0.125–1.353) 0.143
Alpha glucosidase inhibitor 0.335 (0.080–1.406) 0.135
DPP4 inhibitor 1.247 (0.603–2.578) 0.551
eGFR, mL/min/1.73 m2 0.999 (0.979–1.019) 0.908
Total cholesterol, mg/dL 1.006 (0.995–1.018) 0.273
LDL-cholesterol, mg/dL 1.015 (1.002–1.029) 0.023 1.018 (1.005–1.032) 0.005
HDL-cholesterol, mg/dL 0.991 (0.968–1.015) 0.468
Ln (triglyceride) 1.050 (0.531–2.078) 0.889
HbA1c, % 1.029 (0.804–1.317) 0.813
Ln (CACS + 1) 1.311 (1.109–1.549) 0.002
Pericardial fat volume, mL 1.002 (0.996–1.008) 0.536
Significant stenosis 4.750 (2.157–10.264) < 0.001 4.286 (1.764–10.417) 0.001
High-risk plaque 2.850 (1.404–5.786) 0.004 2.076 (0.935–4.612) 0.073
High LAD-PCAT attenuation 2.562 (1.202–5.460) 0.015 2.689 (1.166–6.199) 0.026
Suita score 1.060 (1.019–1.102) 0.004

ACE-I angiotensin-converting enzyme inhibitor; ARB angiotensin-receptor blocker; DPP4 dipeptidyl peptidase-4; eGFR estimated glomerular filtration rate; LDL low-density lipoprotein; HDL high-density lipoprotein; HbA1c glycated hemoglobin A1c; CACS coronary artery calcium score; LAD left anterior descending artery; PCAT pericoronary adipose tissue